



Contact:

Mia West  
West Public Relations LLC  
[mwest@west-pr.com](mailto:mwest@west-pr.com)  
619.501.2756

### **Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact**

*Frequentz provides insight into the transition from lot to serialization-based traceability*

**Palo Alto, CA** – March 31, 2015 – Frequentz Inc., a global leader and champion of supply chain visibility, has released a white paper to help the pharmaceutical industry understand the current and future implications of the 2013 Drug Supply Chain Security Act (**DSCSA**). The white paper, "From Lot-based to Serialization-based Traceability", addresses the various stages of the **GS1 EPCIS Standard(s)** and Implementation Plan rollout, as well as provides a detailed outlook on the product tracing requirements that need to occur between now and the 2017 and 2023 deadlines.

"This week's news out of Europe regarding the Active Pharmaceutical Ingredients supply chain adds momentum to what is becoming a global trend in enhanced **pharmaceutical traceability**," said Haris Kamal, Vice President of Sales, Health and Life Sciences, Frequentz. "While we have yet to see how European pharmaceutical supply chain companies will address their new guidelines, the U.S. supply chain will soon meet an inevitable transition from lot to serialization based traceability. The Frequentz white paper gives the U.S. pharma industry a detailed roadmap of the mandates to help them navigate the changes with ease."

To download a copy of the white paper, visit [http://frequentz.com/news\\_media/download-form-white-paper-lot-serialization-based-traceability/](http://frequentz.com/news_media/download-form-white-paper-lot-serialization-based-traceability/).

### **The Solution**

People everywhere rely on the validity and safety of their medications to help them live healthier lives. As the counterfeit drug market grows and supply chains become more complex, Frequentz provides businesses globally with cutting-edge pharmaceutical management technologies that help monitor products as they move through the supply chain and keep consumers safe. Benefits include:



- Customizable solutions addressing all the major pedigree usage scenarios that pharmaceutical companies require for faster compliance and more operational efficiencies
- Nimble technology that can quickly adapt to current and emerging laws
- ERP and Middleware agnostic with the flexibility to be hosted or on-site, and uniquely in a private cloud for data safety and independent validation procedures
- As a member of GS1 and leader in EPCIS standards since 2006, compliance managers coach clients through upcoming requirements and beyond
- A verification portal for downstream pharmaceutical trading partners that supports 67 percent of all pharmaceuticals distributed across the United States. This provides visibility into a drug's chain of custody/pedigree, as well as offers quick and easy supplier integration
- Mobile technologies that can help put safety right in a patient's hands by allowing them to authenticate a medicine, receive promotional announcements, adhere to refills and receive important, targeted messaging

### **About Frequentz**

Frequentz is a global leader and champion of end-to-end visibility, offering comprehensive traceability, serialization and information management technologies. Their transformative tools bolster businesses and brand reputations by improving productivity, product quality, and profitability. To accomplish this, Frequentz provides valuable insight into end-to-end supply chains, and critical business processes by collecting, storing and analyzing serialized, life history data. Applications of its software are currently used in the life sciences, agricultural, fishery and sustainability, retail, and automotive industries worldwide and promote intelligent analytics and consumer safety. For more information visit [www.frequentz.com](http://www.frequentz.com).

###